BriaCell Therapeutics BCTX Cash Flow Statement (2019-2026)

NASDAQ BCTX
$3.60 +0.14 (+4.05%)
At close: Oct 21, 2026 · 4:00 PM EDT
Reported Financials

BriaCell Therapeutics Quarterly Cash Flow Statement

Periods 24 quarters
Latest Apr 2026

BriaCell Therapeutics reported cash from operations of -$7.02M and free cash flow of -$7.02M for the quarter ended Apr 2026, up 2.0% year over year. This cash flow statement covers 24 quarters of results from Aug 2019 through Apr 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Aug2019 Jul2020 Jan2021 Apr2021 Jul2021 Oct2021 Jan2022 Apr2022 Jul2022 Oct2022 Jan2023 Apr2023 Jul2023 Oct2023 Jan2024 Apr2024 Jul2024 Oct2024 Jan2025 Apr2025 Jul2025 Oct2025 Jan2026 Apr2026
Operating Activities
Net Income
-2.72M-27.53M11.16M-10.02M-0.45M-1.11M-11.88M-4.90M-2.42M5.96M-11.33M1.69M-1.25M-5.83M-6.34M-6.22M-8.16M-8.28M-7.30M-7.24M
Depreciation and DepletionDep. & Depletion
0.02M0.02M0.02M0.02M0.02M0.02M0.03M
Depreciation, Depletion & Amortization
Amortizatization of IntangiblesAmort. of Intangibles
0.00M0.00M0.00M0.00M0.00M0.00M0.00M0.00M
AmortizationAmort.
0.00M
Depreciation & Amortization (CF)Dep. & Amort.
0.00M0.00M0.00M0.00M0.00M0.00M0.00M0.00M0.00M0.00M0.00M0.06M0.02M0.02M0.03M0.01M0.02M0.02M0.03M
Share-based CompensationStock Comp.
-0.04M0.52M0.81M0.86M0.88M1.11M0.27M0.28M0.53M0.53M0.50M0.39M0.38M0.27M0.64M0.22M0.29M0.29M0.43M
Gains from Equity InvestmentsGains Equity
-0.02M-0.04M-0.05M-0.07M-0.04M-0.06M-0.05M-0.04M-0.06M-0.06M
Gains from Investment SecuritiesGains Investment
-0.06M0.03M0.09M0.14M
Other non-cash itemsOther Non-Cash
3.49M25.25M-14.80M5.93M-4.73M-4.12M7.63M-0.54M-5.09M-14.28M1.57M-10.95M-4.58M0.62M-0.81M-0.18M-0.39M0.07M-0.21M-0.12M
Change in Working Capital
Change in ReceivablesChange Receivables
0.00M0.01M0.01M-0.01M0.01M0.01M-0.02M0.01M0.00M0.00M0.01M-0.01M0.74M-0.36M-0.28M0.18M-0.27M-0.89M0.79M0.31M
Change in Account PayablesChange Payables
0.31M0.03M0.28M-0.31M0.24M0.33M-0.21M0.41M0.13M-0.69M3.28M2.71M0.75M-2.94M0.77M-1.72M0.00M-1.15M-0.25M0.29M
Change in Accured ExpensesChange Accured Exp.
-0.15M-0.11M0.07M0.33M-0.30M-0.09M0.30M0.29M-0.07M-0.40M0.12M-0.04M0.46M-0.18M0.82M-0.36M0.49M0.12M0.11M
Change in Other Operating AssetsOther Assets Change
-0.54M-0.11M-0.10M1.38M-0.40M-0.54M-0.31M0.89M4.36M-0.94M1.03M-0.89M-1.33M0.37M-0.29M0.19M-0.76M
Other Working Capital ChangesOther WC Changes
0.54M0.11M0.10M-1.38M0.40M0.54M0.31M-0.89M-4.36M0.94M-1.03M0.89M1.33M-0.37M0.29M-0.19M0.76M
Cash from OperationsCash from Ops.
-1.95M-1.78M-2.56M-4.82M-3.33M-3.54M-3.95M-5.33M-10.92M-7.61M-7.40M-5.08M-4.04M-6.96M-5.92M-7.16M-8.13M-7.70M-7.97M-7.02M
Investing Activities
Purchase of InvestmentsInvestments Purchased
-0.08M0.08M0.08M0.11M7.39M0.08M0.09M15.88M
Cash from Investing ActivitiesCash from Investing
-0.46M-0.08M-0.08M-0.11M-7.39M-0.08M7.28M-16.00M
Financing Activities
Debt Issuance and Repayment
Non-Current Debt
0.13M
Short-Term Debt repaymentsST Debt Repayment
-0.04M
Current Debt
0.04M
Net Debt Issuances and RepaymentsNet Debt Issuance
0.04M0.13M
Change in Capital Stock
Common Stock IssuedStock Issued
1.38M4.00M11.96M5.22M14.71M13.56M
Shares Repurchased
0.01M0.10M0.05M
Net Shares Issued and RepurchasedNet Shares Issued
1.37M-0.10M-0.05M4.00M11.96M5.22M14.71M13.56M
Net Equity Issued and RepurchasedNet Equity Issued
1.37M-0.10M-0.05M4.00M11.96M5.22M14.71M13.56M
Cash from Financing ActivitiesCash from Financing
38.29M1.37M-0.16M-0.05M0.00M4.00M11.96M5.22M14.71M13.56M
Additional items
Exchange Rate EffectFX Effect
Change in Cash
36.35M-1.78M-7.51M-3.45M-3.49M-3.59M-3.95M-5.33M-6.92M-7.61M-7.40M-5.31M-0.07M4.93M-0.78M7.45M-1.97M-7.78M27.19M-23.02M
Ending Cash Balance
57.27M55.49M47.98M44.53M41.04M37.45M33.50M28.17M21.25M13.65M6.24M0.94M0.86M5.79M5.01M12.46M10.49M2.71M29.90M6.88M
Free Cash FlowFCF
-1.95M-1.78M-2.56M-4.82M-3.33M-3.54M-3.95M-5.33M-10.92M-7.61M-7.40M-5.08M-4.04M-6.96M-5.92M-7.16M-8.13M-7.70M-7.97M-7.02M
Net Cash FlowNCF
36.35M-1.78M-2.56M-3.45M-3.49M-3.59M-3.95M-5.33M-6.92M-7.61M-7.40M-5.08M-4.49M4.93M-0.78M7.45M-1.97M-7.78M-0.68M-23.02M

BriaCell Therapeutics Cash Flow Statement API

Pull BriaCell Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=BCTX&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY